Biblio
Export 1170 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is R [Clear All Filters]
“Cerebral Oxidative Stress and Microvasculature Defects in TNF-α Expressing Transgenic and Porphyromonas gingivalis-Infected ApoE-/- Mice.”, J Alzheimers Dis, vol. 60, no. 2, pp. 359-369, 2017.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1291-1295, 2016.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 3, pp. 1055-64, 2016.
, “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
, “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
, “Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.”, J Alzheimers Dis, vol. 55, no. 2, pp. 625-644, 2017.
, “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
, “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
, “Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?”, J Alzheimers Dis, vol. 69, no. 3, pp. 663-669, 2019.
, “Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-β42 Burden in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1085-1090, 2018.
, “Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-β42 Burden in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1085-1090, 2018.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1107-1117, 2018.
, “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
, “Cerebrovascular Disease and Neurodegeneration in Alzheimer's Disease with and without a Strong Family History: A Pilot Magnetic Resonance Imaging Study in Dominican Republic.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1519-1528, 2018.
, “Cerebrovascular Disease and Neurodegeneration in Alzheimer's Disease with and without a Strong Family History: A Pilot Magnetic Resonance Imaging Study in Dominican Republic.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1519-1528, 2018.
, “CFH and ARMS2 Polymorphisms Interact with Zinc Supplements in Cognitive Impairment in the Women's Health Initiative Hormone Trial.”, J Alzheimers Dis, vol. 66, no. 2, pp. 707-715, 2018.
, “Challenges in Screening and Recruitment for a Neuroimaging Study in Cognitively Impaired Geriatric Inpatients.”, J Alzheimers Dis, vol. 56, no. 1, pp. 197-204, 2017.
, “Changes in Frailty Predict Changes in Cognition in Older Men: The Honolulu-Asia Aging Study.”, J Alzheimers Dis, vol. 53, no. 3, pp. 1003-13, 2016.
, “Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 373-81, 2016.
, “Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 373-81, 2016.
, “Changes in Plasma β-NGF and Its Receptors Expression on Peripheral Blood Monocytes During Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1005-1017, 2017.
, “Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.”, J Alzheimers Dis, vol. 51, no. 3, pp. 815-25, 2016.
,